Press Releases Archives - Page 18 of 21

Press Releases

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT033 is an oral formulation of MaaT Pharma’s full-ecosystem biotherapeutic characterized by high microbial diversity and richness Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy Lyon,…

MaaT PharmaNovember 12, 2020

Press Releases

MaaT Pharma Announces Positive Data for its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT

-- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013,…

MaaT PharmaAugust 31, 2020

Press Releases

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

-- Data from the Company’s compassionate use program with MaaT013 as a treatment in patients…

MaaT PharmaAugust 28, 2020

Press Releases

MaaT Pharma Announces Initiation of New Collection and Manufacturing Campaign for its Microbiome Biotherapeutic Product Portfolio

New collection campaign to support future clinical development of microbiome biotherapeutic product portfolio and to…

MaaT PharmaAugust 20, 2020

Press Releases

MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg

Lyon, France, July 16, 2020 – MaaT Pharma announced today the appointment of Claude Bertrand,…

MaaT PharmaJuly 16, 2020

Press Releases

MaaT Pharma annonce la nominationde Savita Bernal en tant que Chief Business Officer

---MaaT Pharma renforce son équipe de direction en ajoutant une expertise en termes de développement…

MaaT PharmaMay 28, 2020

Press Releases

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications

Lyon, France, May 12, 2020 – MaaT Pharma announced today the appointment of leading international…

nboutaouiMay 12, 2020

Press Releases

PR FDA Safety Alert

In response to the recent “FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation…

MaaT PharmaMarch 13, 2020

Press Releases

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B…

nboutaouiJanuary 31, 2020

Press Releases

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B…

MaaT PharmaJanuary 31, 2020

Previous 1 … 16 17 18 19 20 21 Next

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club

Press Releases

Rechercher un article

Filtrer par catégorie

Filtrer par date

Search an article

Filter by category

Filter by date

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT Pharma Announces Positive Data for its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

MaaT Pharma Announces Initiation of New Collection and Manufacturing Campaign for its Microbiome Biotherapeutic Product Portfolio

MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg

MaaT Pharma annonce la nominationde Savita Bernal en tant que Chief Business Officer

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications

PR FDA Safety Alert

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

COMPANY

Ressources

Contact